Drug intelligence / Profile preview

Tetcia

Development stage: Unknown
Lead developer: CanSino Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Tetcia is an adsorbed tetanus vaccine developed by CanSino Biologics. It was granted New Drug Application (NDA) approval by China's National Medical Products Administration (NMPA) in August 2026 for the active immunization against tetanus in adults. Tetcia is manufactured using an animal component-free culture medium fermentation process, which controls the risk of exogenous sensitization at the source while ensuring a stable and well-controlled commercial-scale production process. In a large-scale Phase III clinical study, Tetcia demonstrated a potent immune response and durable protection, achieving high antibody geometric mean concentrations (GMC) and a 98.25% antibody seroconversion rate at six months post-vaccination.

Brand names: Tetcia
Other names: Absorbed Tetanus VaccineAdsorbed Tetanus Vaccine

Beyond the preview

Go deeper on Tetcia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetcia.

Explore the full profile